Trial Profile
Efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2019
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 03 Jun 2019 Results assessing the factors associated with the effectiveness of trifluridine/tipiracil in patients with refractory mCRC (n=160) published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 21 Feb 2018 New trial record
- 20 Jan 2018 Results (n=129) presented at the 2018 Gastrointestinal Cancers Symposium